About this Presentation

This presentation examines global regulatory requirements (including explaining key the differences between NDA vs. ANDA) along with regulatory approaches for bioequivalence and an overview of FDA drug specific guidance. A comparison of FDA, EMA and ANVISA pharmaceutical equivalence (PE) is also discussed along with methods for increasing success for in vitro bioequivalence.

Download Presentation